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CROSSTALK BETWEEN LIPID METABOLISM AND MITOCHONDRIAL 
BIOENERGETICS IN TUBEROUS SCLEROSIS COMPLEX 
TAYLOR R. KAVANAGH 
ABSTRACT 
 
Background  
Tuberous sclerosis complex (TSC) is a multisystem hamartomatous 
disease caused by inactivating mutations in the TSC1/TSC2 genes leading to 
hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) in TSC 
tumors. Novel therapeutic regimens and imaging biomarkers remain critical 
unmet needs in TSC. 
Mitochondrial fatty acid oxidation (FAO) is a major cellular source of 
acetyl-CoA. Acetyl-CoA is a central metabolite in lipid anabolism and catabolism. 
The purpose of this study was to identify novel metabolic therapeutic targets, 
particularly involving lipid metabolism, to achieve durable responses in TSC. 
Methods and Results 
Fluoroacetate (FACE), an acetate derivative, is a surrogate biomarker of 
mitochondrial activity. It accumulates in the mitochondria without being oxidized 
to CO2, and it is converted to fluorocitrate, irreversibly inhibiting the TCA 
(tricarboxylic acid) cycle enzyme aconitase. Micro-positron emission tomography 
(PET) imaging of subcutaneous xenografts of TSC2-deficient Eker rat uterine 
leiomyoma-derived ELT3 cells showed rapid uptake of [18F]FACE that was 
  vi 
maintained after 72-hour treatment with mTORC1 inhibitor rapamycin. This result 
suggests that mitochondrial oxidative metabolism is sustained in the presence of 
rapamycin. 
 Consistent with this finding, treatment of TSC2-deficient cells with 
rapamycin led to a significant increase in FAO and a decrease in glucose 
oxidation in vitro as measured by a 14C-CO2 collection metabolic assay. 
Expression of the A isoform of carnitine palmitoyltransferase I (CPT1A; FAO rate-
limiting enzyme) was selectively increased in TSC2-deficient cells. 
Pharmacological inhibition of CPT1A by ST1326 led to a decrease in FAO, as 
measured by a 14C-CO2 collection metabolic assay, and a decrease in 
mitochondrial ATP production, measured by the Seahorse analyzer.  
Conclusions  
This study proposes a role for FAO in TSC tumor bioenergetics and for 
CPT1A as a potential therapeutic target in TSC. 
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INTRODUCTION  
 
Tuberous sclerosis complex (TSC) is a multisystem hamartomatous 
disease caused by inactivating mutations in the TSC1 or TSC2 gene. It is an 
autosomal dominant disorder that leads to hyperactivation of mammalian target 
of rapamycin complex 1 (mTORC1) in TSC tumors, including subependymal 
giant cell astrocytoma (SEGA) of the brain, facial angiofibromas, cardiac 
rhabdomyomas, renal angiomyolipomas, renal cell carcinomas, and pulmonary 
lymphangioleiomyomatosis (LAM) (Carsillo, Astrinidis, & Henske, 2000; Henske, 
Jóźwiak, Kingswood, Sampson, & Thiele, 2016). Renal cell carcinoma is found in 
2%-4% of TSC patients (Yang et al., 2014). LAM is a diffuse proliferation of 
smooth muscle actin-positive cells (LAM cells) of uncertain origin associated with 
cystic lung destruction, leading to progressive decline in pulmonary function and 
eventually to dependence on oxygen supplementation. Up to 80% of female 
patients with TSC develop LAM (Cudzilo et al., 2013). LAM can also occur as a 
sporadic disorder in which LAM cells harbor somatic mutations of the TSC1 or 
TSC2 gene (Carsillo et al., 2000). Sporadic LAM can be characterized by renal 
angiomyolipomas, lymphangiomyomas, and lymph node abnormalities.  
Rapamycin is an mTORC1 inhibitor approved by the Food and Drug 
Administration (FDA) for the treatment of TSC-associated renal 
angiomyolipomas, TSC-associated SEGAs, and LAM. However, rapamycin 
exerts a cytostatic but not cytotoxic effect on tumor cells. This is suggested by in 
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vitro and preclinical studies as well as clinical trials (Bissler et al., 2013; 
McCormack et al., 2011). Specifically, rapamycin stabilizes pulmonary function 
(as measured by FEV1, forced expiratory volume in 1 second) in LAM patients 
and decreases the volume of renal angiomyolipomas. Upon termination of 
rapamycin treatment, lung function declines, and tumor growth resumes (Bissler 
et al., 2008; McCormack et al., 2011). Therapeutic regimens able to induce tumor 
cell death and durable responses are a critical need in TSC and LAM.  
mTORC1 is a master regulator of cell growth and metabolism (Figure 1). It 
is a serine/threonine kinase complex that has been shown to regulate a wide 
array of cellular metabolic processes (Ben-Sahra, Howell, Asara, & Manning, 
2013; Ben-Sahra, Hoxhaj, Ricoult, Asara, & Manning, 2016; Csibi et al., 2013; 
Düvel et al., 2010; Egan, Kim, Shaw, & Guan, 2011; Laplante & Sabatini, 2009; 
Peterson et al., 2011; Priolo et al., 2015). mTORC1 is regulated by the TSC 
complex, and biallelic loss of TSC1 or TSC2 abolishes the negative regulatory 
effects on mTORC1, thus activating it.  
A major direct target of mTORC1 is S6 kinase, which has several 
downstream targets initiating an anabolic cellular state. S6 kinase 
phosphorylates S6 ribosomal protein and the eukaryotic translation initiation 
factor 4B (EIF4B), which both stimulate messenger RNA (mRNA) translation, 
leading to ribosome biogenesis and protein synthesis (Holz, Ballif, Gygi, & Blenis, 
2005; Kwiatkowski & Manning, 2014). Carbamoyl-phosphate synthetase 2, 
aspartate transcarbamoylase, dihydroorotase (CAD) is also phosphorylated by 
 3 
S6 kinase, activating de novo pyrimidine biosynthesis, while de novo purine 
synthesis is also increased through the mitochondrial tetrahydrofolate cycle, 
increasing the available nucleotide pools for DNA and RNA synthesis (Ben-Sahra 
et al., 2013, 2016).  
mTORC1 regulates lipid metabolism in a number of ways: (1) 
phosphorylating lipin1, which is a phosphatidate phosphatase that prevents 
activation of the lipogenic transcription factor sterol regulatory element binding 
protein (SREBP) 1/2 (Peterson et al., 2011); (2) regulating the transcriptional 
activity of SREBP, therefore inducing transcription of genes involved in de novo 
lipid synthesis (Horton, Goldstein, & Brown, 2002), and (3) inducing the pentose 
phosphate pathway (PPP) to generate reduced nicotinamide adenine 
dinucleotide phosphate (NADPH), which is required for de novo lipid synthesis 
(Düvel et al., 2010). As a result of these processes, TSC2-deficient cells have 
abnormal lipid synthesis and content, including elevated levels of choline 
phospholipids and neutral lipids (Priolo et al., 2015). 
In a mechanism that remains largely unstudied, mTORC1 increases the 
transcription of hypoxia-inducible factor 1 (HIF1A), which then increases the 
expression of glucose transporters and glycolytic enzymes, promoting aerobic 
glycolysis (Düvel et al., 2010).  
Collectively, all of these anabolic processes lead to an increase in cell size 
and growth in an mTORC1-activated setting (Figure 1). Although anabolic 
mechanisms are activated by mTORC1, a main catabolic cellular process, 
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autophagy, is inhibited by direct phosphorylation of the serine/threonine-protein 
kinase ULK1 (Egan et al., 2011) and potentially the transcription factor EB 
(TFEB) (Settembre et al., 2012).  
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Figure 1. mTORC1 is a master regulator of cell growth and metabolism. Graphical 
representation of mTORC1 downstream targets and impact on metabolism. Dotted lines 
represent indirect targets; solid lines represent direct targets; capped lines represent 
inhibitory function. CAD = Carbamoyl-phosphate synthetase 2, aspartate 
transcarbamoylase, dihydroorotase; EIF4B= Eukaryotic translation initiation factor 4B; 
HIF1a= Hypoxia-inducible factor 1; mTORC1= mammalian target of rapamycin 
complex 1; SREBP= Sterol regulatory element binding protein; TSC1/2= Tuberous 
sclerosis complex 1/2; 4EBP1= EIF4E binding protein 1 . Figure adapted from 
Kwiatkowski et al., 2014.  
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Acetyl-CoA is a central metabolite at the crossroads of lipid metabolism 
(synthesis and catabolism) and cell proliferation (Figure 2). Acetyl-CoA in the cell 
is vital for fatty acid/sterol synthesis, protein/histone acetylation, and 
mitochondrial oxidative phosphorylation (Hosios & Vander Heiden, 2014). Acetyl-
CoA can be directly derived from the action of acetyl-CoA synthetase on 
endogenous or exogenous acetate, a major source of cellular energy. Other 
major sources of acetyl-CoA are pyruvate (oxidative decarboxylation by the 
pyruvate dehydrogenase enzymatic complex), amino acids, and fatty acids (fatty 
acid oxidation [FAO or β-oxidation] in the mitochondria and peroxisomes) (Hosios 
& Vander Heiden, 2014; Pietrocola, Galluzzi, Bravo-San Pedro, Madeo, & 
Kroemer, 2015). FAO is a major cellular energy source that is often a relevant 
player in cancer cell metabolism (Carracedo, Cantley, & Pandolfi, 2013; 
Carracedo et al., 2012; Pacilli et al., 2013). The rate-limiting step of FAO is 
catalyzed by carnitine palmitoyltransferase 1 (CPT1) (Qu, Zeng, Liu, Wang, & 
Deng, 2016; Wong et al., 2017). 
 
 7 
 
 
Figure 2. Mitochondrial fatty acid oxidation (FAO) is a major source of acetyl-CoA. 
Graphical representation of lipid biosynthesis and fatty acid oxidation pathways. 
Carnitine palmitoyltransferase 1 (CPT1) is responsible for shuttling long-chain fatty acids 
into the mitochondria for oxidation. ACC =Acetyl-CoA carboxylase;  AMPK = 5’- AMP 
activated protein kinase; ChoK= Choline kinase; CPT1= Carnitine palmitoyltransferase 
1; FA= Fatty acids; FASN= Fatty acid synthase; NADPH= Nicotinamide adenine 
dinucleotide phosphate; PPP= Pentose phosphate pathway; SREBP= Sterol regulatory 
element binding protein; TAG= Triacylglycerides; TCA= Tricarboxylic acid. Figure taken 
from (Kavanagh & Priolo, 2016). 
 
 
Carnitine palmitoyltransferase 1 (CPT1) transports long-chain fatty acids 
into the mitochondria from the cytoplasm for oxidation. The enzyme lies on the 
outer mitochondrial membrane and converts acyl-CoA and carnitine to 
acylcarnitine (Figure 3). CPT1 exists in three isoforms: A, B, and C. CPT1A and 
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CPT1B are inhibited by malonyl-CoA, the product of the first committed step in 
fatty acid synthesis. CPT1A has a higher affinity for malonyl-CoA than CPT1B, 
making it the more critical enzyme in the rate-limiting step of FAO (Bonnefont et 
al., 2004; Casals et al., 2016; Schreurs, Kuipers, & Van Der Leij, 2010; Wong et 
al., 2017). In the mitochondria, CPT1 translocates acyl-CoA and carnitine across 
the outer mitochondrial membrane, where they are converted to acylcarnitine. 
CACT (carnitine acylcarnitine translocase) translocates acylcarnitine across the 
inner mitochondrial membrane (Rosca, Lemieux, & Hoppel, 2009) where CPT2 
(carnitine palmitoyltransferase 2) converts it back to acyl-CoA and carnitine for 
use in FAO (Console, Giangregorio, Indiveri, & Tonazzi, 2014) (Figure 3). 
Many cancers are found to have upregulation of CPT1 isoforms, and 
inhibition of CPT1 in cancer cells has been proven to reduce proliferation and to  
impact other cancer phenotypes (Qu et al., 2016).  
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Figure 3. The carnitine-acyltransferase system. CPT1 (carnitine palmitoyltransferase 
1) catalyzes the rate-limiting step of fatty acid oxidation by shuttling long chain fatty acids 
across the outer mitochondrial membrane to be oxidized. FAO is a major source of 
acetyl-coA in the cell. CACT= Carnitine acylcarnitine translocase; CPT2 = Carnitine 
palmitoytransferase 2. 
 
FAO is a largely unstudied metabolic pathway in TSC. Its contribution to 
the lipid homeostasis and cellular bioenergetics in cells with constitutively active 
mTORC1 (due to inactivating TSC mutations) remains widely unknown.  
Rapamycin is an allosteric inhibitor of mTORC1 and is the only FDA-approved 
drug for the treatment of TSC and LAM. Clinical trials with rapamycin have 
shown that upon discontinuation of treatment, there is a resumption of tumor 
growth and pulmonary function decline, highlighting the crucial need for durable 
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therapeutic regimens in TSC (Bissler et al., 2013; McCormack et al., 2011). 
Targeting metabolic vulnerabilities in TSC tumor cells, such as lipid metabolism, 
may provide a potential target for sustainable cytotoxic therapy. 
 
Objectives  
The overall goals of this study are to determine whether there is a role for 
FAO in TSC mitochondrial bioenergetics and tumorigenesis, and to determine 
whether this potential role can be exploited as a therapeutically targetable 
metabolic vulnerability in the treatment of TSC.   
The objectives of this study are (1) to assess the effects of mTORC1 
suppression by rapamycin on the mitochondrial bioenergetics of TSC2-deficient 
cells, (2) to determine the expression of the various isoforms of CPT1 in different 
TSC2-deficient and isogenic TSC2 add-back cell lines, and (3) to evaluate the 
impact of pharmacologic and genetic inhibition of CPT1 on FAO, mitochondrial 
bioenergetics, cellular lipid accumulation, and cell fitness in TSC2-deficient cells.  
 11 
METHODS 
 
Cell Lines and Preclinical Models of TSC  
 TSC2-deficient ELT3 cells were derived from Eker rat uterine leiomyoma 
as previously described (Astrinidis et al., 2002; Howe et al., 1995). TSC2 -/- and 
TSC2 +/+ mouse embryonic fibroblasts (MEFs), originally derived from littermate 
control animals (Zhang et al., 2003), were gifted by Dr. David Kwiatkowski 
(Brigham and Women’s Hospital, Boston, MA). LAM patient-derived renal 
angiomyolipoma 621-101 cells (Yu, Astrinidis, Howard, & Henske, 2004) (gift of 
Dr. Elizabeth Henske, Brigham and Women’s Hospital, Boston, MA) carry the 
same biallelic TSC2 gene-inactivating somatic mutations as the patient’s LAM 
cells (Carsillo et al., 2000), with a G1832A missense mutation in one allele and 
the other allele completely lost. The 621-101 cells were transfected with an 
empty vector or a vector expressing the TSC2 gene, developing the 621-102 
(TSC2-null) and 621-103 (TSC2-re-expressing) cell lines, respectively (Furukawa 
et al., 1996; Yu et al., 2004). All cell lines were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 100 units of penicillin, 100 mg/mL of 
streptomycin, and 10% fetal bovine serum (FBS). All cell lines were validated for 
proper TSC2 deficiency, mTORC1 activation, and response to rapamycin using 
immunoblotting for tuberin (TSC2) and phospho-S6 kinase. 
 The in vivo model, as described by Verwer et al. (2018) and generated for 
use in the positron emission tomography (PET) studies, was done by 
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subcutaneous injection of ELT3 cells into intact mice. Female NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice (JAX stock #005557, The Jackson Laboratory, Bar 
Harbor, ME) were injected in the flank with a 1:1 mixture of 2.5 million cells 
resuspended in 100 L of phosphate-buffered saline (PBS) and Matrigel (BD 
Biosciences, San Jose, CA). Mice were imaged 6-8 weeks after cell injection 
(Verwer et al., 2018). 
 
Genetic Silencing of CPT1A   
TSC2 -/- and TSC2 +/+ MEFs were infected with lentiviral short hairpin 
RNA (shRNA) for CPT1A (pLKO library, lentiviral mouse Cpt1a shRNA obtained 
through The RNAi Consortium, Broad Institute, Cambridge, MA). Three different 
shRNA constructs were used, and the two best CPT1A genetic knockdowns 
were selected. Silencing was confirmed by western blot.  
 
Drug Treatments in vitro and in vivo  
For in vivo PET imaging, rapamycin (LC Laboratories, Woburn, MA) was 
dissolved in absolute ethanol (20 mg/mL), diluted in sterile vehicle (0.25% Tween 
80/0.25% polyethylene glycol [PEG] 200 in distilled water), and then 
administered as an intraperitoneal injection (i.p.) using a 27G needle (3 
mg/kg/day; 100 µL maximum volume). A 20 nM dose of rapamycin dissolved in 
absolute ethanol was used for all in vitro drug treatments. Etomoxir (Millipore 
Sigma, St. Louis, MO) was purchased in solution (H2O) as a 50 mM stock (2 
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mg/118 L) and was diluted to 50 M for in vitro drug treatments. ST1326 (Avanti 
Polar Lipids, Inc., Alabaster, AL) was dissolved in dimethyl sulfoxide (DMSO) (2 
mg/mL) to make a 5 mM stock solution. The ST1326 stock solution was diluted to 
50 M for in vitro drug treatments. 
 
Synthesis of [18F]FACE 
[18F]FACE was synthesized following previously published methods 
(Ponde et al., 2007) with minor modifications by the Gordon Center for Medical 
Imaging at Massachusetts General Hospital (Boston, MA). 
 
PET Imaging  
 [18F]FACE-PET imaging was performed using a Siemens microPET 
Focus 220 PET/CT (positron emission tomography/computed tomography) 
(Siemens Preclinical Solutions, Knoxville, TN).  Five mice were imaged before 
and after a 72-hour treatment with rapamycin, and 5 mice were imaged before 
and after a 72-hour treatment with the vehicle (0.25% Tween 80/0.25% PEG 200 
in distilled water) as a control. PET data were collected for 90 minutes after 
anesthetization with isoflurane, tail vein cannulation, and injection of 200 Ci of 
tracer using a 30G needle. A dynamic sequence of images was reconstructed, 
and standardized uptake value (SUV) maps were generated using 
semiquantitative analysis that considered injected dose and mouse body weight. 
Fusion of functional PET and anatomical CT images helped to localize tumors. 
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Fusion figures were generated using MatLab (MathWorks, Natick, MA) (Verwer 
et al., 2018). 
 
De novo Lipid Synthesis 
 Lipids were extracted from ELT3 cells following 6-hour labeling with either 
[1-14C]acetic acid or [1-14C]FACE (0.5 Ci/mL) obtained from American 
Radiolabeled Chemicals (ARC, Saint Louis, MO). Cells were washed three times, 
and lipids were collected using methanol/chloroform/water (2:1:0.5 v/v/v). 
Radioactivity was counted on a Packard Tri-Carb Liquid Scintillation Analyzer 
(Verwer et al., 2018).  
  Human renal angiomyolipoma-derived 621-102 cells were treated for 23 
hours with ST1326 (50 M) or DMSO (control).  Lipids were extracted from these 
cells and from 621-103 cells (treated with control only) following 6-hour labeling 
with [1-14C]acetic acid (0.5 Ci/mL) (PerkinElmer, Inc., Waltham, MA). Cells were 
washed three times, and lipids were collected using isopropanol. Radioactivity 
was counted on a Packard Tri-Carb Liquid Scintillation Analyzer. 
 
[1-14C]FACE Cellular Incorporation 
ELT3 cells were treated for 24 hours with either DMSO (vehicle) or 
rapamycin (20 nM). Cells were labeled for 6 hours with [1-14C]FACE, washed 
three times, and collected. Radioactivity was counted on a Packard Tri-Carb 
Liquid Scintillation Analyzer (Verwer et al., 2018).  
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14C-Nutrient Oxidation  
TSC2-deficient and expressing MEFs were seeded in 12-well plates and 
treated with rapamycin (20 nM) for 24 hours. The cells were then incubated for 3 
hours at 37 C with 1 Ci/mL of [U-14C]glucose, [U-14C]glutamine, or [U-
14C]palmitate obtained from American Radiolabeled Chemicals (ARC, Saint 
Louis, MO). Perchloric acid (3M) was added to the culture medium, and the 
dishes were sealed with phenylethylamine (Sigma-Aldrich Corporation, St. Louis, 
MO)-saturated Whatman filter paper as previously reported (Parkhitko et al., 
2014). The plates were gently shaken for 3 hours at room temperature, and the 
filter paper was collected and placed into Ultima Gold F Scintillation Fluid 
(PerkinElmer, Inc., Waltham, MA). Radioactivity, as measured by 14C-CO2, was 
counted on a Packard Tri-Carb Liquid Scintillation Analyzer (Verwer et al., 2018).  
Human renal angiomyolipoma-derived 621-102 and 621-103 cells were 
seeded in 12-well plates and treated with rapamycin (20 nM), ST1326 (50 M), or 
a combination of the two for 23 hours. The cells were labeled for 3 hours with [U-
14C]palmitate or D-[U-14C]glucose (Perkin Elmer, Inc., Waltham, MA), and the 
same procedure was followed as described for 14C-CO2 collection. 
  
Seahorse Analyzer 
ELT3 cells were treated for 20 hours with vehicle (DMSO), rapamycin (20 
nM), [19F]FACE (40 mM; ABX advanced biochemical compounds GmbH, 
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Radeberg, Germany), or the combination of rapamycin and [19F]FACE. The 621-
102 and 621-103 cells were treated for 24 hours with vehicle (DMSO), rapamycin 
(20 nM), or ST1326 (50 M). The oxygen consumption rate (OCR) was 
measured under basal conditions and various drug conditions (oligomycin, 1 M; 
trifluoromethoxy carbonylcyanide phenylhydrazone [FCCP], 1.5 M; combination 
of antimycin A, 0.5 M, and rotenone, 0.5 M) using the Seahorse Bioscience 
XF24 analyzer (Seahorse Bioscience, North Billerica, MA), as previously 
described (Parkhitko et al., 2014). Oligomycin is an inhibitor of ATP synthase 
(complex V) of the electron transport chain; FCCP is responsible for uncoupling 
oxygen consumption from ATP production, and rotenone and antimycin A inhibit 
both complex I and III of the electron transport chain, respectively. Results were 
normalized using crystal violet staining measurements.  
 
Citrate Metabolite Measurement 
 Metabolites were extracted on dry ice from ELT3 cells that were treated 
with vehicle (DMSO), rapamycin, [19F]FACE, or the combination of rapamycin 
and [19F]FACE using 80% aqueous methanol precooled at -80 C. An internal 
standard of [D8]-valine (Cambridge Isotope Laboratories, Inc., Tewksbury, MA) 
was added during metabolite extraction. Insoluble materials were removed by 
centrifugation, and supernatant was evaporated to dryness using a SpeedVac at 
42 C. The pellet was resuspended in liquid chromatography-mass spectrometry 
(LC-MS) grade water, and metabolites were analyzed by LC-MS at a Brigham 
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and Women’s Hospital metabolite facility (Harvard Medical School, Boston, MA). 
The obtained metabolite data were expressed as ratios of peak areas of target 
metabolite to internal standard. Ratios were normalized to total cell proteins 
determined by a parallel experiment. 
 
Immunoblotting  
 Total protein extractions were performed using 15-minute incubation with 
Nonidet P-40 lysis buffer (Roche Applied Science, Penzberg, Germany). Proteins 
were run on Bolt Bis-Tris Plus polyacrylamide gels (Life Technologies, Carlsbad, 
CA). Tuberin (cat# 4308S) was obtained from Cell Signaling Technology 
(Danvers, MA); CPT1A (cat# ab128568) was obtained from Abcam (Cambridge, 
UK); Beta-actin (cat# A5316) was obtained from Sigma (St. Louis, MO). Primary 
antibodies were diluted 1:1000 in either 5% milk or 5% bovine serum albumin in 
Tris-buffered saline with 0.5% Tween 20, following the manufacturer’s 
instructions. Nitrocellulose membranes were probed for the primary antibodies 
overnight at 4 C. 
 
ATP Measurement 
 Both TSC2-/- and TSC2+/+ MEFs were seeded in 96-well plates, and 
adenosine triphosphate (ATP) production was measured over the course of 72 
hours using a CellTiter-Glo Luminescent Cell Viability Assay (Promega Corp., 
Madison, WI). The 621-101 cells were similarly assayed after 24-hour treatment 
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with DMSO (vehicle) or ST1326 (50 M). Measurements at each time point were 
compared relative to baseline measurements. 
 
Neutral Lipid Staining 
Cells were seeded on glass-bottom 35 mm dishes and treated overnight 
with DMSO (vehicle), rapamycin (20 nM), etomoxir (50 M), or ST1326 (50 M) 
for 24 hours. Cells were fixed with 4% paraformaldehyde, washed with PBS, and 
incubated with fluorescent dyes boron-dipyrromethene (BODIPY) 493/503 
(1:1000 dilution, 2 g/mL final concentration) and 4՛ ,6-diamidino-2-phenylindole 
(DAPI) (1:2000 dilution, 2.5 g/mL final concentration). Images were taken with a 
60x objective using a FluoView FV-10i Olympus Laser Point Scanning Confocal 
microscope (Olympus Scientific Solutions Americas Corporation, Waltham, MA).  
 
Statistical Analysis  
Statistical analysis was performed on GraphPad Prism 5 (GraphPad 
Software, San Diego, CA). Reported data were represented as median values 
unless noted otherwise. Statistical significance was defined as p < 0.05. 
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RESULTS 
 
Uptake of Fluoroacetate (FACE) is Sustained upon Rapamycin Treatment in 
TSC2-deficient Cells in vivo 
Fluoroacetate (FACE) is a surrogate biomarker of mitochondrial activity. It 
is an acetate derivative that is converted in the mitochondria into fluorocitrate, 
which irreversibly inhibits the tricarboxylic acid (TCA) cycle enzyme aconitase, 
the enzyme responsible for the conversion of citrate to isocitrate (Figure 4A). 
FACE is not oxidized to CO2 and therefore accumulates in the mitochondria. 
Acetate, in contrast, is both oxidized to CO2 in the mitochondria and incorporated 
into lipids.   
A recent study (Verwer et al., 2018) published [18F]FACE micro-positron 
emission tomography (PET) imaging of subcutaneous xenografts of TSC2-
deficient Eker rat uterine leiomyoma-derived ELT3 cells (Howe et al., 1995). In 
this study, mice were scanned for 90 minutes after injection with 200 Ci of 
tracer, and a dynamic series of images were reconstructed. Standardized uptake 
value (SUV) maps were generated using semiquantitative analysis that 
considered injected dose and mouse body weight. The fusion of functional PET 
and anatomical computed tomography (CT) images helped to localize tumors. 
Reconstructed images showed rapid uptake of [18F]FACE in the xenograft 
tumors. No significant change in tumor tracer uptake was seen in mice treated 
with rapamycin (3 mg/kg/day) for 72 hours versus the vehicle control (Figure 4B) 
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(Verwer et al., 2018). Images are shown at timepoints 30-40 minutes post-
injection (p.i.) and 80-90 minutes p.i. Yellow/white regions in the PET/CT images 
depict high uptake, which can be seen in the tumor pre- and post-treatment with 
rapamycin. These results were quantified by the percentage change in SUVmean  
pre- and post-treatment with rapamycin or vehicle (Figure 4C). These data 
suggest that mitochondrial oxidative metabolism is sustained in the presence of 
rapamycin.  
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Figure 4. [18F]Fluoroacetate-PET of TSC2-deficient xenografts shows no change in 
uptake with rapamycin treatment. (A) Fluoroacetate mechanism of action. (B) PET/CT 
images (tumor PET/CT fusion, left panels; whole body PET/CT fusion, right panels) of a 
rapamycin-treated (72-hour) and a vehicle-treated mouse. (C) Percentage change in 
SUVmean before and after 72-hour treatment with rapamycin or vehicle. Each dot 
represents an individual xenograft; n=5, p<0.05. Kruskal-Wallis test with Dunn’s multiple 
comparisons test was applied. Results are shown as mean ± SD.  CT = Computerized 
tomography; PET = Positron emission tomography; p.i. = post-injection; Rapa = 
Rapamycin; SUV = Standardized uptake value. Figure adapted from (Verwer et al., 
2018). 
 22 
FACE Regulates Mitochondrial Respiration in TSC2-deficient Cells  
 To determine if the lack of change in vivo in [18F]FACE uptake during 
rapamycin treatment depends on the metabolic fate of fluoroacetate in the cell, a 
number of metabolic assays were performed. Consistent with the in vivo data, 
there was no significant difference observed in cellular incorporation of [1-
14C]FACE between vehicle (DMSO)-treated and rapamycin-treated cells (Figure 
5A) (Verwer et al., 2018), further suggesting that mitochondrial oxidative 
metabolism is sustained during rapamycin treatment.  
To confirm the specificity of the in vitro and in vivo results, testing was 
done in which ELT3 cells were first labeled with either [1-14C]FACE or [1-
14C]acetate in 10% serum media for 6 hours. Lipids were extracted using 
methanol/chloroform (2:1 v/v) and counted for radioactivity. As expected, [1-
14C]FACE was not found incorporated into lipids, whereas [1-14C]acetate was 
incorporated into lipids (Figure 5B) (Verwer et al., 2018).  
To validate the hypothesis that mitochondrial oxidation is sustained during 
rapamycin treatment, two different approaches were used. First, using the 
Seahorse analyzer, mitochondrial oxygen consumption rate (OCR) was 
measured in TSC2-deficient cells treated with rapamycin, FACE, or the 
combination of rapamycin and FACE. Oligomycin, which inhibits ATP synthase 
(complex V) of the electron transport chain, will decrease OCR correlating to the 
cellular contribution of mitochondrial respiration to ATP production. FCCP, an 
uncoupler, will completely disrupt the proton gradient and mitochondrial 
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membrane potential, allowing uninhibited electron flow through the electron 
transport chain and maximal oxygen consumption of the cells.  Treatment with 
rotenone and antimycin A shuts down mitochondrial respiration and 
demonstrates residual non-mitochondrial respiration in the cells (Seahorse XF 
Cell Mito Stress Test Kit User Guide, n.d.). Rapamycin alone did not suppress 
OCR; however, both FACE and the combination of FACE and rapamycin 
significantly suppressed basal respiration and maximal respiratory capacity in 
TSC2-deficient cells (Figure 5C) (Verwer et al., 2018).  
Next, under the same experimental conditions, the levels of citrate, the 
substrate of aconitase, were measured using LC-MS. Significant accumulation of 
citrate was seen in TSC2-deficient cells treated with FACE and FACE plus 
rapamycin. Rapamycin alone did not induce this accumulation (Figure 5D) 
(Verwer et al., 2018). Taken together, these data support the in vivo data and the 
hypothesis that rapamycin-insensitive uptake of fluoroacetate by TSC tumors 
reflects a metabolic feature that is specific to TSC2-deficiency. 
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Figure 5. FACE regulates mitochondrial respiration and is not incorporated into 
lipids. (A) Total cellular radioactivity was counted following 24-hour rapamycin or vehicle 
(DMSO) treatment and 6-hour [1-14C]FACE labeling of ELT3 cells. (B) Lipids were 
extracted from ELT3 cells following 6-hour labeling with [1-14C]acetate or [1-
14C]fluoroacetate (FACE). (C) ELT3 cells treated for 20 hours with rapamycin (20 nM), 
fluoroacetate (40 mM), or both were analyzed by the Seahorse assay. Data are 
expressed as a percentage relative to the basal DMSO OCR rate, and a two-way 
ANOVA was applied. (D) ELT3 cells treated for 20 hours with rapamycin (20 nM), 
fluoroacetate (40 mM), or both were analyzed by LC-MS for citrate levels. One-way 
ANOVA with Tukey’s multiple comparison test was applied. Results are shown as mean 
± SD (n =5); ***p < 0.001. ANOVA = Analysis of variance; CPM = Counts per minute; 
DMSO = Dimethyl sulfoxide; FCCP = Trifluoromethoxy carbonylcyanide 
phenylhydrazone; LC-MS= Liquid chromatography-mass spectrometry; OCR = Oxygen 
consumption rate; Rapa = Rapamycin. Figure taken from (Verwer et al., 2018). 
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Rapamycin Selectively Induces FAO and Acetate Oxidation in TSC2-
deficient Cells 
Acetyl-CoA is a central metabolite at the crossroads of lipid synthesis and 
catabolism. Cellular pools of acetyl-CoA are derived from sources of pyruvate 
(glucose and amino acids) and fatty acid -oxidation (Hosios & Vander Heiden, 
2014; Pietrocola et al., 2015). In order to determine the effect of rapamycin on 
acetate oxidation in the cell, mitochondrial acetate oxidation was previously 
tested using [1-14C]acetate, and an increase in this process in ELT3 TSC2-
deficient cells was found upon treatment with rapamycin (Verwer et al., 2018). To 
determine if rapamycin induces preferential usage of different nutrient sources of 
acetyl-CoA, experiments were done with TSC2-deficient (TSC2-/-) and TSC2-
expressing (TSC2+/+) mouse embryonic fibroblasts (MEFs; isolated by David 
Kwiatkowski [Zhang et al., 2003]) in which the cells were incubated with [U-
14C]glucose, [U-14C]glutamine, or [U-14C]palmitate for three hours. 14C-CO2 was 
collected and used as a readout of mitochondrial oxidative processes (CPM/g 
proteins). The results in Figure 6 show that rapamycin significantly decreased 
glucose oxidation while increasing palmitate oxidation in TSC2 -/- MEFs. 
Glutamine oxidation was unchanged in the TSC2 -/- MEFs; however, glutamine 
oxidation was enhanced in the TSC2 +/+ MEFs, which were negative for FAO 
(data not shown). These results suggest that exogenous fatty acids are a 
preferential energy source for mitochondrial oxidation in TSC2-deficient cells. 
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Taken together, these data suggest that there is a switch in preferential 
mitochondrial oxidation substrate by TSC2-deficient cells upon cytostasis 
induced by rapamycin treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Rapamycin selectively induces fatty acid oxidation (FAO) and acetate 
oxidation in TSC2-deficient cells. Following 24-hour treatment with rapamycin, TSC2-
/- mouse embryonic fibroblasts (MEFs) were labeled for 3 hours with [U-14C]glucose, [U-
14C]glutamine, or [U-14C]palmitate. 14C-CO2 was subsequently collected and counted. 
Results are shown as mean ± SD (n = 3); **p < 0.01 Rapa = Rapamycin ; TSC = 
Tuberous sclerosis complex; Vehicle = DMSO. 
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Carnitine Palmitoyltransferase 1 Isoform A is Selectively Expressed by 
TSC2-deficient Cells 
   To determine the mechanism underlying preferential usage of fatty acids 
as nutrient sources of acetyl-CoA under rapamycin treatment, testing was 
completed on the expression of CPT1, the rate-limiting enzyme of fatty acid 
oxidation, in TSC2-deficient cells.  A panel of TSC2-deficient cells were assayed 
for isoform A and isoform B of CPT1. Human renal angiomyolipoma-derived 
TSC2-deficient 621-101 cells (Carsillo et al., 2000; Furukawa et al., 1996; Yu et 
al., 2004) and TSC2-/- and TSC2 +/+ MEFs were analyzed for the expression of 
CPT1A and CPT1B. Immunoblotting results showed selective expression of 
CPT1A in TSC2-deficient cells (Figure 7).  
 
Figure 7. Carnitine palmitoyltransferase 1 isoform A (CPT1A) is selectively  
expressed by TSC2-deficient cells. Immunoblotting revealed selective expression of 
CPTI A in human renal angiomyolipoma-derived TSC2-deficient 621-101 cells and in 
TSC2-/- MEFs. Beta-actin was the loading control. CPT1B = Carnitine 
palmitoyltransferase 1B; MEFs = Mouse embryonic fibroblasts; TSC = Tuberous 
sclerosis complex.   
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CPT1A Downregulation Increases Lipid Droplet Accumulation and 
Decreases Metabolic Fitness in TSC2-deficient Cells 
To further explore the effect of CPT1A downregulation on mitochondrial 
homeostasis in TSC2-deficient cells, silencing of CPT1A was achieved by 
infection of TSC2-deficient and TSC2-expressing MEFs with two lentiviral shRNA 
constructs (Figure 8A). To test the effect of CPT1A silencing on cellular 
metabolic fitness, an assay was set up in which TSC2-deficient and TSC2-
expressing MEFs with shCPT1A were seeded and relative measurements of 
ATP (luminescence) were taken every 24 hours for 3 days (Figure 8B). A steady 
decrease in luminescence was measured relative to baseline over a 72-hour 
period in the TSC2-deficient cells with CPT1A silencing. Over the same time 
period, no change was observed in TSC2-expressing MEFs. Crystal violet 
staining was done in parallel to confirm equal cell seeding (data not shown). 
These results suggest a selective effect of CPT1A on metabolic fitness and 
homeostasis in TSC2-deficient cells.  
The shCPT1A and shcontrol cells were then stained with BODIPY 
493/503 to detect lipid droplets (green fluorescence). Downregulation of CPT1A 
resulted in a remarkable accumulation of lipid droplets compared with shcontrol 
(Figure 9). This accumulation was not seen in the TSC2-expressing MEFs with 
shCPT1A silencing. The accumulation of lipid droplets in this setting is likely due 
to the inhibition of fatty acid channeling into the mitochondrial matrix for 
mitochondrial oxidation. The CPT1 inhibitor, etomoxir (ETX; 50 µM), was used as 
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a positive control, with the mTOR inhibitor rapamycin serving as a negative 
control (Figure 9). Similar to genetic silencing of CPT1A, etomoxir induced an 
increase in lipid droplet accumulation, whereas rapamycin induced a decrease in 
lipid droplet staining, consistent with an increase in FAO. These results 
demonstrate efficient and effective inhibition of CTP1A activity by the two shRNA 
constructs and support the theory that CPT1A activity is not redundant in TSC2-
deficient cells. 
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Figure 8: CPT1A downregulation decreases metabolic fitness in TSC2-deficient 
cells. (A) Silencing of CPT1A  was achieved in TSC2-deficient MEFs by infection with 
lentiviral shRNA. Beta-actin was the loading control. (B) TSC2-deficient MEFs with 
shCPT1A silencing showed significant decreases in ATP levels as measured by 
luminescence relative to baseline over a 72-hour period. Results are shown as mean 
±SD (n = 4; p < 0.05). ATP = Adenosine triphosphate; CPT = Carnitine 
Palmitoyltransferase; GFP = Green fluorescent protein; MEFs = Mouse embryonic 
fibroblasts; TSC = Tuberous sclerosis complex. 
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Figure 9. CPT1A downregulation increases lipid accumulation in TSC2-deficient 
cells. TSC2 -/- and TSC2 +/+ MEFs with shCPT1A and TSC2 -/- MEFs were treated for 
24 hours with DMSO, rapamycin (20 nM), or etomoxir (ETX, 50 µM). The cells were 
stained with DAPI (nuclei) and BODIPY (lipid droplets). Scale bars: 40 μm (Rapa, ETX); 
50 μm (all others). CPT = Carnitine Palmitoyltransferase; BODIPY= Boron-
dipyrromethene; DAPI= 4՛ ,6-diamidino-2-phenylindole; DMSO= Dimethyl sulfoxide; 
ETX= Etomoxir; GFP = Green fluorescent protein; MEFs = Mouse embryonic fibroblasts; 
Rapa= Rapamycin; TSC = Tuberous sclerosis complex. 
 
Rapamycin-induced FAO in Human Renal Angiomyolipoma-derived Cells is 
Suppressed by Pharmacological Inhibition of CPT1A 
To further confirm the role of the A isoform of CPT1 in metabolic 
homeostasis, testing was carried out with human renal angiomyolipoma-derived 
621-101 cells and ST1326, a specific inhibitor for CPT1A. The 621-101 cells 
were treated with either vehicle (DMSO) or ST1326 (50 µM) for 24 hours, and the 
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cells were stained with BODIPY 493/503 (Figure 10A). A remarkable increase in 
lipid droplet accumulation was detected, confirming the role of CPT1A in fatty 
acid channeling for oxidation.  
The 621-101 cells were then seeded in a 96-well format, and relative ATP-
measurements were taken after 24 hours of DMSO or ST1326 treatment (50 µM) 
(Figure 10B). A significant decrease in ATP, as determined by luminescence 
relative to baseline, was observed. This effect was consistent with the results 
seen in the TSC2-deficient MEFs with CPT1A shRNA silencing. These results 
suggest a selective effect of CPT1A on the energy homeostasis of TSC2-
deficient cells. The results also support the hypothesis that CPT1A inhibition 
triggers the use of metabolic signaling and mechanisms to compensate for the 
lack of fatty acid channeling into FAO for cellular energy.  
 To confirm the previous results with TSC2-deficient and TSC2-expressing 
MEFs, analysis of FAO levels was completed on human renal angiomyolipoma-
derived cells that were TSC2-deficient and TSC2-re-expressing. FAO levels were 
measured by 14C-CO2 after 3-hour incubation with [U-14C]palmitate. As previously 
seen, the TSC2-deficient cells demonstrated significantly higher levels of FAO 
than the cells with re-expressing TSC2 (Figure 10C).      
 To verify the effect of pharmacological inhibition of CPT1A, an assay was 
performed using human renal angiomyolipoma-derived 621-101 cells that were 
infected with either an empty vector (621-102; TSC2-null) or a TSC2-expressing 
vector (621-103; TSC2-expressing). The cells were treated for 23 hours with 
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rapamycin (20 nM), ST1326 (CPT1A inhibitor; 50 µM), or a combination of the 
two. The cells were then labeled for 3 hours with [U-14C]palmitate, and 14C-CO2 
was collected and counted as a readout of FAO (Figure 10D). ST1326 was found 
to induce a significant decrease in the TSC2-null (621-102) cells that could not 
be compensated for by the combination with rapamycin. As expected, rapamycin 
induced a significant increase in FAO in the TSC2-null cells. These results 
confirm the critical role of CPT1A in FAO that is specific for TSC2-deficient 
settings. 
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Figure 10. Rapamycin-induced FAO in human renal angiomyolipoma-derived cells 
is suppressed by pharmacological inhibition of CPT1A. (A) 621-101 cells were 
stained with BODIPY and DAPI after treatment for 24 hours with vehicle (DMSO) or 50 
µM ST1326 (CPT1A inhibitor; dose based on independent assessment of FAO 
inhibition). Scale bar: 40 μm. (B) 621-101 cells were treated for 24 hours with ST1326 
(50 µM), and ATP levels were measured by luminescence relative to baseline. (C) 
TSC2-deficient human renal angiomyolipoma cells (621-102) and the TSC2-re-
expressing cells (621-103) were incubated for 3 hours with [U-14C]palmitate, and 14C-
CO2 was collected and counted. (D) Following 23-hour treatment with rapamycin (20 
nM), ST1326 (50 μM), or both rapamycin and ST1326, 621-102 and 621-103 cells were 
labeled for 3 hours with [U-14C]palmitate, and 14C-CO2 was collected and counted. 
Results are shown as mean ± SD (n = 6). ***p < 0.001; **p < 0.01; *p < 0.05 ATP 
=Adenosine triphosphate; BODIPY= Boron-dipyrromethene; CPM = Counts per minute; 
CPT = Carnitine palmitoyltransferase; DAPI= 4՛ ,6-diamidino-2-phenylindole; DMSO = 
Dimethyl sulfoxide; FAO = Fatty acid oxidation; Rapa = Rapamycin; TSC = Tuberous 
sclerosis complex.  
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De novo Lipid Synthesis is Enhanced in TSC2-deficient Cells and is Further 
Increased by Treatment with ST1326 
 To further analyze the effects of CPT1A inhibition on lipid metabolism, de 
novo lipid synthesis assays were performed to determine baseline levels of lipid 
synthesis, as well as levels after treatment with ST1326 and rapamycin. The 621-
102 (TSC2-null) and 621-103 (TSC2-expressing) cells were labeled for 6 hours 
with [1-14C]acetate, and lipids were extracted in isopropanol to evaluate baseline 
differences between these two cells lines. As expected, the 621-102 (TSC2-null) 
cells upregulated de novo lipid synthesis because of hyperactivated mTORC1 
activity compared with the TSC2-re-expressing 621-103 cells (Figure 11A).  
Next, TSC2-null 621-102 cells were treated for 23 hours with either the 
control (DMSO) or the CPT1A pharmacological inhibitor, ST1326 (50 µM). The 
cells were incubated for 6 hours with [1-14C]acetate, and lipids were collected in 
isopropanol. As shown in Figure 11B, ST1326 treatment significantly increased 
de novo lipid synthesis, suggesting a potential metabolic switch toward synthesis 
when CPT1A, and therefore FAO, is inhibited. This result is consistent with the 
increase in lipid accumulation seen in Figure 10A. Lipid accumulation upon 
ST1326 treatment could be due in part to the suppression of FAO and in part to 
an increase in de novo lipid synthesis.  
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Figure 11. De novo lipid synthesis is enhanced in TSC2-deficient cells and is 
further increased by treatment with ST1326. (A) Following 6-hour incubation with [1-
14C]acetate, lipids were extracted from 621-102 and 621-103 cells using isopropanol, 
and radioactivity was counted (n=6). Unpaired t-test was applied. (B) 621-102 cells were 
treated for 23 hours with ST1326 (50 µM) or control (DMSO). Cells were incubated for 6 
hours with [1-14C]acetate, and lipids were collected in isopropanol. Radioactivity was 
counted following collection. Unpaired t-test was applied. Results are shown as mean ± 
SD (n = 4). **p < 0.01 CPM = Counts per minute; DMSO = Dimethyl sulfoxide; TSC = 
Tuberous sclerosis complex.  
 
Pharmacological Inhibition of FAO Significantly Alters Mitochondrial 
Glucose and Oxidative Metabolism 
FAO is a critical biological pathway in TSC2-deficient cells, and the 
implications of its inhibition in a TSC2-deficient setting are largely unknown. To 
further determine the effect of FAO inhibition on mitochondrial metabolism, an 
experiment was performed in which human renal angiomyolipoma-derived 621-
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102 (TSC2-null) and 621-103 (TSC2-re-expressing) cells were treated for 23 
hours with rapamycin (20 nM), ST1326 (50 M), a combination of the two, or 
DMSO (vehicle). The cells were labeled for 3 hours with D-[U-14C]glucose, and 
14C-CO2 was collected and counted as a readout for glucose oxidation. In Figure 
12A, the combination of rapamycin and ST1326 showed significant increases in 
glucose oxidation in both cells, whereas rapamycin alone showed a trend toward 
a decrease in glucose oxidation. These data suggest a potential switch in 
preference of oxidation substrate when mTORC1 and FAO are both 
simultaneously inhibited.  
To further explore the impact of ST1326 inhibition of CPT1A on 
mitochondrial oxidation, the Seahorse analyzer was used to measure 
mitochondrial oxygen consumption rate (OCR) in both 621-102 and 621-103 cells 
treated with rapamycin, ST1326, or vehicle (DMSO) (Figure 12B). ST1326 
significantly reduced basal respiration in both cell lines, with more drastic 
changes seen in the TSC2-deficient (621-102) cells. ATP production was 
significantly decreased by ST1326 treatment in the TSC2-deficient cells, 
although it had no effect on ATP production in the TSC2-expressing (621-103) 
cells, as measured during oligomycin treatment. It is worth noting that basal, 
maximum respiration, and non-mitochondrial respiration were all significantly 
increased in the 621-102 cells compared with the 621-103 cells, as measured by 
background OCR, FCCP, and antimycin and rotenone treatment, respectively. 
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These data suggest a more specific effect on mitochondrial respiration in TSC2-
deficient cells upon FAO inhibition.  
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Figure 12. Pharmacological inhibition of FAO significantly alters  
mitochondrial glucose and oxidative metabolism. (A) Following 23-hour treatment 
with rapamycin (20nM), ST1326 (50M), both rapamycin and ST1326, or vehicle 
(DMSO), 621-102 and 621-103 cells were labeled for 3 hours with D-[U-14C]glucose and 
14C-CO2 was collected and counted. Results are shown as mean ± SD. *p < 0.05. (B) 
Seahorse assay of 621-102 and 621-103 cells treated with rapamycin (20 nM, 24 hours), 
ST1326 (50 M, 24 hours), or vehicle (DMSO). Data are expressed as a percentage 
relative to the basal DMSO OCR rate. Two-way ANOVA was applied. Results are shown 
as mean ± SD (n =6) ****p < 0.0001; *p < 0.05 CPM = Counts per minute; DMSO = 
Dimethyl sulfoxide; FAO = Fatty acid oxidation; FCCP = Trifluoromethoxy 
carbonylcyanide phenylhydrazone; OCR = Oxygen consumption rate; Rapa = 
Rapamycin.  
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DISCUSSION 
 
Acetyl-CoA is a central nutrient in cellular metabolism. It contributes to 
both biosynthetic pathways, including lipid (de novo fatty acid and cholesterol) 
synthesis, and mitochondrial oxidative metabolism. This study focused on the 
role of mitochondrial oxidative metabolism in TSC2-deficient cells, which have 
hyperactive mTORC1. In a recent publication, the potential for [18F]FACE-PET 
was tested in vivo as a mitochondrial activity biomarker in preclinical models of 
TSC (Verwer et al., 2018). Tumor SUV values for [18F]FACE were found to be 
high at baseline and unchanged after 72-hour treatment with rapamycin. This 
result suggests that mitochondrial metabolism of TSC2-deficient cells is 
sustained rather than suppressed upon rapamycin treatment. Consistent with 
this, Seahorse analysis of TSC2-deficient cells treated with rapamycin, FACE, or 
the combination of the two, showed that OCR was not affected by rapamycin. 
More important, FACE suppressed OCR, alone and in the presence of 
rapamycin.  In addition, [14C]FACE incorporation in TSC2-deficient cells grown on 
plastic was unchanged after 24-hour treatment with rapamycin. Taken together, 
these results reflect the sustained mitochondrial activity and mitochondrial 
accumulation of the tracer that was seen in vivo (Verwer et al., 2018).  
 Pools of acetyl-CoA in the cell derive from both endogenous and 
exogenous sources. Sources of acetyl-CoA include acetate, glucose, pyruvate, 
amino acids that generate acetyl-CoA or pyruvate, and fatty acids. In our 
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experiments, TSC2-deficient cells showed preferential usage of certain nutrients 
for mitochondrial oxidation upon rapamycin treatment. Glucose oxidation 
appeared to be strictly regulated upon mTORC1 hyperactivation and was 
suppressed by treatment with rapamycin. Intriguingly, FAO was elevated at 
baseline when mTORC1 was hyperactive, and further increased with rapamycin 
treatment when mTORC1 was suppressed. These results suggest that multiple, 
rapamycin-independent pathways may regulate selective consumption of 
nutrients in mitochondrial oxidative processes in TSC tumors. This hypothesis is 
supported by both in vivo and in vitro experiments from this study. The ability to 
nutrient switch represents a potentially unique metabolic feature of TSC tumors 
under mTORC1 suppression that could be therapeutically targeted.  
 Interestingly, TSC2-deficient cells selectively express the liver isoform of 
CPT1 (CPT1A). CPT1A is the rate-limiting step enzyme in mitochondrial FAO 
and regulates the transfer of long-chain fatty acids across the outer mitochondrial 
membrane. CPT1A downregulation in TSC2-deficient cells both genetically and 
pharmacologically showed significant shifts in mitochondrial metabolism, 
including decreases in FAO, increases in neutral lipid accumulation, and 
decreases in mitochondrial ATP production. Thus, CPT1A likely represents a 
potential therapeutic target for the treatment of TSC. 
Rapamycin is an FDA-approved, FKBP12-dependent allosteric inhibitor of 
mTORC1 that is approved for the treatment of LAM and TSC-associated tumors. 
However, its inability to kill tumor cells and induce durable clinical responses 
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upon discontinuation (Bissler et al., 2013, 2008; McCormack et al., 2011) results 
in a critical need for cytotoxic therapies in the treatment of TSC. Thus, CPT1A 
inhibitors may provide a possible metabolic therapeutic intervention for the 
treatment of TSC.            
Etomoxir is an irreversible inhibitor of CPT1 that was designed for the 
treatment of chronic congestive heart failure and type II diabetes mellitus 
(Bristow, 2000; Hübinger, Weikert, Wolf, & Gries, 1992; Schmidt-Schweda & 
Holubarsch, 2000). In more recent years, etomoxir has been shown to 
demonstrate some anti-cancer effects (Tirado-Vélez, Joumady, Sáez-Benito, 
Cózar-Castellano, & Perdomo, 2012); however, it is still in the preclinical stage 
(Carracedo et al., 2013) because of toxicity effects (Merrill et al., 2002).   
ST1326, also known commercially as Teglicar, was developed as a 
reversible inhibitor of the liver isoform of CPT1, CPT1A (Giannessi et al., 2003). 
As it is specific for the A isoform, ST1326 provides a more direct and specific 
inhibition of the isoform of interest. ST1326 has been used in the treatment of 
type II diabetes mellitus, for which it is currently in phase II clinical trials. More 
recently, ST1326 has been in the limelight for its promising use in cancer studies, 
specifically leukemias (Pacilli et al., 2013; Ricciardi et al., 2015; Samudio & 
Konopleva, 2015). ST1326 has the potential to be an effective pharmacological 
agent for use in TSC because of its specificity for the A isoform that is selectively 
expressed by TSC2-deficient cells.  
 
 43 
Conclusions and Implications for Further Research  
In summary, disruption of metabolic homeostasis in TSC2-deficient cells 
appears to provide a window for therapeutic intervention. TSC2-deficient cells 
express a specific metabolic signature under rapamycin treatment, 
demonstrating sustained mitochondrial metabolism upon mTORC1 inhibition. 
FAO may represent a critical energy source for TSC2-deficient cells to survive 
during rapamycin treatment. Commercially available inhibitors of FAO, such as 
etomoxir and ST1326, are available and should be further tested as single 
agents or in combination with rapamycin in preclinical models of TSC in vivo.  
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